vs
Side-by-side financial comparison of OneSpan Inc. (OSPN) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $65.9M, roughly 1.1× OneSpan Inc.). OneSpan Inc. runs the higher net margin — 17.5% vs -49.0%, a 66.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 4.1%).
OneSpan Inc. is an information security company based in Boston, Massachusetts. Services include an internet fraud prevention platform, multi-factor authentication tools and electronic signature software.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
OSPN vs VRDN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $65.9M | $70.6M |
| Net Profit | $11.6M | $-34.6M |
| Gross Margin | 73.6% | — |
| Operating Margin | 22.5% | -56.7% |
| Net Margin | 17.5% | -49.0% |
| Revenue YoY | 4.1% | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $0.39 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $65.9M | — | ||
| Q4 25 | $62.9M | — | ||
| Q3 25 | $57.1M | $70.6M | ||
| Q2 25 | $59.8M | — | ||
| Q1 25 | $63.4M | — | ||
| Q4 24 | $61.2M | — | ||
| Q3 24 | $56.2M | — | ||
| Q2 24 | $60.9M | — |
| Q1 26 | $11.6M | — | ||
| Q4 25 | $43.5M | — | ||
| Q3 25 | $6.5M | $-34.6M | ||
| Q2 25 | $8.3M | — | ||
| Q1 25 | $14.5M | — | ||
| Q4 24 | $28.8M | — | ||
| Q3 24 | $8.3M | — | ||
| Q2 24 | $6.6M | — |
| Q1 26 | 73.6% | — | ||
| Q4 25 | 73.6% | — | ||
| Q3 25 | 73.6% | — | ||
| Q2 25 | 73.5% | — | ||
| Q1 25 | 74.3% | — | ||
| Q4 24 | 74.0% | — | ||
| Q3 24 | 73.9% | — | ||
| Q2 24 | 66.2% | — |
| Q1 26 | 22.5% | — | ||
| Q4 25 | 19.9% | — | ||
| Q3 25 | 14.4% | -56.7% | ||
| Q2 25 | 17.6% | — | ||
| Q1 25 | 27.1% | — | ||
| Q4 24 | 19.3% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 12.5% | — |
| Q1 26 | 17.5% | — | ||
| Q4 25 | 69.2% | — | ||
| Q3 25 | 11.4% | -49.0% | ||
| Q2 25 | 13.9% | — | ||
| Q1 25 | 22.9% | — | ||
| Q4 24 | 47.1% | — | ||
| Q3 24 | 14.7% | — | ||
| Q2 24 | 10.8% | — |
| Q1 26 | $0.39 | — | ||
| Q4 25 | $1.13 | — | ||
| Q3 25 | $0.17 | — | ||
| Q2 25 | $0.21 | — | ||
| Q1 25 | $0.37 | — | ||
| Q4 24 | $0.73 | — | ||
| Q3 24 | $0.21 | — | ||
| Q2 24 | $0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.8M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $272.0M | $503.0M |
| Total Assets | $383.1M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $49.8M | — | ||
| Q4 25 | $70.5M | — | ||
| Q3 25 | $85.6M | $490.9M | ||
| Q2 25 | $92.9M | — | ||
| Q1 25 | $105.2M | — | ||
| Q4 24 | $83.2M | — | ||
| Q3 24 | $77.5M | — | ||
| Q2 24 | $63.8M | — |
| Q1 26 | $272.0M | — | ||
| Q4 25 | $271.8M | — | ||
| Q3 25 | $238.3M | $503.0M | ||
| Q2 25 | $242.5M | — | ||
| Q1 25 | $231.1M | — | ||
| Q4 24 | $212.5M | — | ||
| Q3 24 | $194.6M | — | ||
| Q2 24 | $178.6M | — |
| Q1 26 | $383.1M | — | ||
| Q4 25 | $397.7M | — | ||
| Q3 25 | $343.5M | $577.1M | ||
| Q2 25 | $357.1M | — | ||
| Q1 25 | $333.8M | — | ||
| Q4 24 | $338.7M | — | ||
| Q3 24 | $289.3M | — | ||
| Q2 24 | $286.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 2.44× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $28.2M | — | ||
| Q4 25 | $12.6M | — | ||
| Q3 25 | $11.3M | $-84.6M | ||
| Q2 25 | $6.2M | — | ||
| Q1 25 | $29.4M | — | ||
| Q4 24 | $12.4M | — | ||
| Q3 24 | $14.0M | — | ||
| Q2 24 | $2.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | $9.6M | — | ||
| Q3 25 | $8.8M | $-84.7M | ||
| Q2 25 | $4.4M | — | ||
| Q1 25 | $27.7M | — | ||
| Q4 24 | $10.5M | — | ||
| Q3 24 | $12.0M | — | ||
| Q2 24 | $26.0K | — |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | — | ||
| Q3 25 | 15.4% | -120.1% | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 43.8% | — | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 21.4% | — | ||
| Q2 24 | 0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | 4.7% | — | ||
| Q3 25 | 4.4% | 0.2% | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | 3.2% | — | ||
| Q3 24 | 3.5% | — | ||
| Q2 24 | 3.7% | — |
| Q1 26 | 2.44× | — | ||
| Q4 25 | 0.29× | — | ||
| Q3 25 | 1.74× | — | ||
| Q2 25 | 0.75× | — | ||
| Q1 25 | 2.02× | — | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.69× | — | ||
| Q2 24 | 0.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OSPN
| Product and license | $35.5M | 54% |
| Services and other | $30.4M | 46% |
VRDN
Segment breakdown not available.
